Xylem’s third-quarter revenue came in roughly $80 million below Wall Street’s estimate, and adjusted EPS fell short of consensus. An investigation into potential securities law violations is reviewing losses suffered by XYL shareholders.

NEW YORK, Oct. 27, 2026 /PRNewswire/ — About $80 million in expected revenue was missing when Xylem Inc. (NYSE: XYL) reported third-quarter results on October 27, 2026, and the stock fell as the market reacted to the miss. If you bought XYL shares and are now holding losses, act today. Shareholders who lost money are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Wall Street expected third-quarter revenue of approximately $2.28 billion. Xylem reported approximately $2.20 billion, a shortfall of about 3.5%. The results were shy of the company’s projections as well. Xylem cut full-year revenue projections from “roughly 9.2 billion” to “approximately $8.95 billion.” Adjusted earnings per share came in at $1.44, below consensus estimates of about $1.45.

Xylem attributed the quarter’s results to project delays and cautious customer spending. The October 27 report missed on both the top line and the bottom line. Levi & Korsinsky is investigating whether XYL shareholders may have been harmed by potential securities law violations.

If you purchased Xylem stock and suffered a loss, request a free review of your XYL losses or call (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the XYL Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Xylem Inc. made materially false or misleading statements regarding its business, operations, and customer demand environment. When the Company disclosed third-quarter revenue of approximately $2.20 billion against analyst estimates of approximately $2.28 billion, the stock price declined.

Q: When did Xylem allegedly mislead investors?A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What is the XYL securities fraud investigation about?A: A securities investigation is pending concerning Xylem Inc. (NYSE: XYL) regarding potentially materially false or misleading statements. Shares fell after the Company disclosed third-quarter revenue of approximately $2.20 billion versus estimates of approximately $2.28 billion, along with adjusted EPS of $1.44 versus consensus of about $1.45.

Q: What do XYL investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my XYL shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought XYL and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/xylem-inc-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-xylem-inc-xyl-302921352.html

SOURCE Levi & Korsinsky, LLP